OTCMKTS:QBIOQ BioMed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Q BioMed Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.89 +0.02 (+1.07 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$1.87Now: $1.89▼$1.9150-Day Range$1.72MA: $1.97▼$2.2452-Week Range$0.34Now: $1.89▼$3.75Volume42,601 shsAverage Volume138,359 shsMarket Capitalization$42.63 millionP/E RatioN/ADividend YieldN/ABeta2.59 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Q BioMed. Previous Next 2.6 Community Rank Outperform VotesQ BioMed has received 146 “outperform” votes. (Add your “outperform” vote.)Underperform VotesQ BioMed has received 137 “underperform” votes. (Add your “underperform” vote.)Community SentimentQ BioMed has received 51.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Q BioMed and other stocks. Vote “Outperform” if you believe QBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldQ BioMed does not currently pay a dividend.Dividend GrowthQ BioMed does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Q BioMed insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Q BioMed are expected to grow in the coming year, from ($0.50) to ($0.30) per share. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:QBIO Previous SymbolNASDAQ:QBIO CUSIPN/A CIK1596062 Webwww.qbiomed.com Phone212-588-0022Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-7.27Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,280,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-1,653.37%Miscellaneous Employees1 Outstanding Shares22,558,000Market Cap$42.63 million Next Earnings Date7/16/2020 (Estimated) OptionableNot Optionable OTC:QBIO Rates by TradingView Receive QBIO News and Ratings via Email Sign-up to receive the latest news and ratings for QBIO and its competitors with MarketBeat's FREE daily newsletter. Q BioMed (OTCMKTS:QBIO) Frequently Asked Questions How has Q BioMed's stock been impacted by COVID-19 (Coronavirus)? Q BioMed's stock was trading at $1.5728 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QBIO shares have increased by 20.2% and is now trading at $1.89. View which stocks have been most impacted by Coronavirus. When is Q BioMed's next earnings date? Q BioMed is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Q BioMed. How were Q BioMed's earnings last quarter? Q BioMed Inc (OTCMKTS:QBIO) posted its quarterly earnings results on Monday, April, 13th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.13. View Q BioMed's earnings history. Has Q BioMed been receiving favorable news coverage? Press coverage about QBIO stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Q BioMed earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutQ BioMed. Who are some of Q BioMed's key competitors? Some companies that are related to Q BioMed include Tiziana Life Sciences (TLSA), CELYAD SA/ADR (CYAD), Chembio Diagnostics (CEMI), Advanz Pharma (CXRXF), Mustang Bio (MBIO), Aquestive Therapeutics (AQST), Aptinyx (APTX), Newron Pharmaceuticals (NWPHF), Sol Gel Technologies (SLGL), Endonovo Therapeutics (ENDV), Immunic (IMUX), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), BIOFRONTERA AG/ADR (BFRA) and Sierra Oncology (SRRA). View all competitors. What other stocks do shareholders of Q BioMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include Washington Trust Bancorp (WASH), Micron Technology (MU), NVIDIA (NVDA), Otonomy (OTIC), Canopy Growth (CGC), New Age Beverages (NBEV), Opko Health (OPK), Adobe (ADBE), Advanced Micro Devices (AMD) and Cyberark Software (CYBR). Who are Q BioMed's key executives? Q BioMed's management team includes the following people: Mr. Denis D. Corin, Chairman, CEO, Pres & CFO (Age 46)Mr. William S. Rosenstadt, Gen. Counsel & Director (Age 51)Mr. David Laskow-Pooley, VP of Product Devel. (Age 65)Mr. Robert Derham, VP of Orphan ProductsMr. Ari Jatwes, Bus. Devel. Analyst What is Q BioMed's stock symbol? Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO." How do I buy shares of Q BioMed? Shares of QBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Q BioMed's stock price today? One share of QBIO stock can currently be purchased for approximately $1.89. How big of a company is Q BioMed? Q BioMed has a market capitalization of $42.63 million. Q BioMed employs 1 workers across the globe. What is Q BioMed's official website? The official website for Q BioMed is www.qbiomed.com. How can I contact Q BioMed? Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 212-588-0022. This page was last updated on 6/2/2020 by MarketBeat.com Staff
